Occlutech Obtains CE Mark for the new Generation PFO & ASD... ( JENA Germany May 12 /- Occlutech ...)

Occlutech Obtains CE Mark for the new Generation PFO & ASD Occluders

Date:5/12/2009

JENA, Germany, May 12 /PRNewswire/ -- Occlutech, the leading European developer of septum occluders, today announced that it has obtained CE mark approval for its new generation ASD and PFO occluders, the Figulla Flex.

The Figulla Flex ASD and PFO occluders encompass a new innovative delivery system, making the use of a threaded hub unnecessary. The implantation of the occluder is facilitated by the ability of the delivery system to allow a 45 degree angle before release.

The Occlutech Figulla Flex will be exhibited and demonstrated at the PCR vascular intervention meeting in Barcelona from May 19th to May 22nd.

Occlusion devices are used to treat structural heart disease, including structural heart defects and abnormalities such as Atrial Septal Defects, (ASD), and Patent Foramen Ovale (PFO, an undesired channel between the heart's two atria, present in up to 25% of the population), in minimally invasive, non-surgical procedures. The market for PFO occluders is expected to expand significantly as the link between PFO and stroke, that is the third most common cause of death, as well as severe migraine becomes increasingly well documented.

    Contact:

    Tor Peters
    info@occlutech.de
    Tel: +49-3641-67-51-29

    Katrin Biedermann
    katrin.biedermann@occlutech.de
    Tel.: +49-3641-67-51-20

0

GOOD

Page: 1
Related medicine news :

1. AGA Medical Corporation Begins Proceedings Against Occlutech to Recover Damages
2. AGA Medical to Appeal Ruling by Dutch Court in Lawsuit With Occlutech GmbH
3. Occlutech Wins Confirmation of its Intellectual Property Position Versus AGA Medical Patent by AIPPI
4. Hard To Treat Diseases (HTDS) Obtains HAS Certificate
5. American Biotech Labs(R) Obtains FDA Approval for New Wound Care Gel Product
6. High dosage brachytherapy obtains excellent results in head and neck tumors
7. China Sky One Medical, Inc. Obtains SFDA Approval for Policresulen Vaginal Suppositories
8. Cynosure Obtains Favorable Markman Rulings in Patent Infringement Case Against CoolTouch
9. Nostrum Pharmaceuticals Obtains Worldwide Licensing Rights From IMTECH for Clinical Development of the Small Molecule Caerulomycin and Its Proprietary Derivatives for Their Novel Indication of Immunosuppression
10. Steve Teal, Santa Rosa Attorney, Obtains $850,000 for Client in Highest Hospital Negligence Verdict in Mendocino County
11. New York Attorney Obtains $2.25 Million Verdict for Client Injured on Grounds of Bronx Eye Surgery Clinic

Post Your Comments:

Occlutech Obtains CE Mark for the new Generation PFO & ASD...( JENA Germany May 12 /- Occlutech ...),Health